V
V. Wee Yong
Researcher at University of Calgary
Publications - 276
Citations - 21024
V. Wee Yong is an academic researcher from University of Calgary. The author has contributed to research in topics: Multiple sclerosis & Microglia. The author has an hindex of 73, co-authored 233 publications receiving 17556 citations. Previous affiliations of V. Wee Yong include Allen Institute for Brain Science & Foothills Medical Centre.
Papers
More filters
Journal ArticleDOI
Matrix metalloproteinases in intracerebral hemorrhage
Mengzhou Xue,V. Wee Yong +1 more
TL;DR: The experimental data support the use of pharmacologic anti-matrix metalloproteinases strategies in the acute periods following intracerebral hemorrhage to alleviate injury.
Journal ArticleDOI
Monocytes increase human cardiac myofibroblast-mediated extracellular matrix remodeling through TGF-β1
Holly E.M. Mewhort,Brodie D Lipon,Daniyil A. Svystonyuk,Guoqi Teng,David G. Guzzardi,Claudia Silva,V. Wee Yong,Paul W.M. Fedak +7 more
TL;DR: Direct cell-cell interaction between monocytes and cardiac myofibroblasts stimulates TGF-β-mediated myofIBroblast activity and increases remodeling of local matrix in a three-dimensional ECM microenvironment, suggesting inflammation as a potential driver of cardiac fibrosis.
Journal ArticleDOI
A quantitative analysis of suspected environmental causes of MS.
TL;DR: A very significant negative correlation between MS prevalence and available ultraviolet (UV) radiation is reported and the available ultraviolet radiation is a significant environmental factor, moreso than all the other factors examined.
Journal ArticleDOI
Regenerative Capacity of Macrophages for Remyelination
TL;DR: This review will discuss the beneficial roles of macrophages/microglia in remyelination and discuss therapeutic strategies to obtain the optimal regenerative macrophage phenotype for enhanced remYelination.
Journal ArticleDOI
Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome.
TL;DR: Modification of the microbiome, the use of probiotics, fecal microbiota transplantation, supplementation with bile acids and intestinal barrier enhancers are all promising candidates and hopefully, pre-clinical studies and clinical trials will soon yield significant results.